MOLNUPIRAVIR

EIDD-2801/MK-4482

ABOUT MOLNUPIRAVIR

Molnupiravir

has been in the news lately as the Active Pharmaceutical Ingredient ("API") in the Investigational Oral Anti-Viral manufactured by drug-maker Merck to treat COVID-19. It is also the API in MOLCOVIR 200mg, the COVID-19 Anti-Viral developed by Optimus Drugs Private Ltd. in India for which EAU and patent protection is being sought in that nation. Optimus is among the world's primary manufacturers of Molnupiravir.

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS.

OPTIMUS IS AMONG THE WORLD'S PRIMARY MANUFACTURERS OF MOLNUPIRAVIR

WHAT IS AN API?

Active Pharmaceutical Ingredients i.e., API refers to an active ingredient that is contained in the medication. For instance, the active ingredient for relieving pain is incorporated in the painkiller. It is called API. Even its small amount has a powerful impact, so only a mere part of this active ingredient is contained in the medicine. Moreover, you will find its amount and name contained in the medication on the OTC (over-the-counter) drugs' package.

Elements of Medicines

Every drug is made up of two core elements i.e., the API that is the major ingredient, as well as the excipient, which are the substances other than drugs that support delivery of the medicine to the system. The excipients are chemically inactive compounds, like mineral oil or lactose in the pill. The Active Pharmaceutical Ingredient is compounded in different doses (see below) with the excipients to create the final "formulation."

APIs' strength

The API manufacturers utilize specific standards for determining how strong it is in every drug. However, it can widely vary from brand-to-brand. Every brand may utilize distinctive test tactics, which can lead to distinctive potencies. In every case, the FDA needs the manufacturers to prove their products' potency in real-life patients along with the lab conditions.

Click Here to read full article.

OPTIMUS

Three Indian pharmaceutical firms lead the supply of the active pharmaceutical ingredient (API, or the key raw material) of Molnupiravir—the investigational oral antiviral medicine that has just been found to be effective in treating Covid-19 patients.

Melissa Barber, a Harvard University researcher who did a cost estimation to arrive at a sustainable generic price for Molnupiravir has identified the three Telangana based firms—**Optimus Drugs Private Ltd, Honour Lab, and Maithri Laboratories**—as the global source for Molnupiravir API. Barber's observation comes in a yet to be peer-reviewed working paper jointly written by her and Dzintars Gotham of Kings College Hospital London.

Click Here to read full article.

EUA APPROVED COUNTRIES

HOW MANY COUNTRIES HAVE FULLY APPROVED MOLNUPIRAVIR FOR PUBLIC USE?

None, this product is being sold to countries with their expectation of approval sometime in the near future. Each independent country has their own "FDA" type entity through which clinical trials are performed and drug is approved or not-approved. Other nations, such as Viet Nam, have already purchased quantities for "experimental" usage.

IF A COUNTRY ISN'T APPROVED, HOW CAN THEY PURCHASE MOLNUPIRAVIR?

A Government agency can bring anything into the country that it elects (approves) to do so. The USA purchased 1.7 M courses of the Molnupiravir. FDA clearance is still at least 60 days off. Through a "Authorized Government" agency, a Government authorization letter has to be issued from the Buying country specifically stating their Country has fully authorized the importing of the Molnupiravir drug from XYZ company for the amount of XXX,XXX,XXX doses. This approval is based on proper filings of export country India, completing a proper Exportation License Filing for the same Molnupiravir. The USA has "pre-purchased."

ALLOCATION AVAILABILITY



45 MILLION

Available Right Now

30 MILLION

Available November 15, 2021

30 MILLION

Available December 15, 2021,

30 MILLION

Available January 15, 2021,

PACKAGING

Packaging is in blister packs with 10 pills per pack and 10 packs per box (100 pills per box)

STANDARD OPERATING PROCEDURE

1

ISSUE PO

2

SPA ISSUED BUY SELLER

3

ESCROW AGREEMENT ISSUED AND SIGNED

4

GOVERNMENT AUTHORIZATION LETTER BY BUYING COUNTRY

5

SELLER TO RELEASE TO BUYER THE FOLLOWING DOCUMENT

A. Allocation from Manufacturer to distributor
B. Bill of Ladings from Manufacturer to Allocation holder with production batch numbers.
C. Product report
D. Export License to your Country as well as your Bill of Lading.

6

TRANSFER MONIES INTO ESCROW.

7

INSPECT

8

SHIP

THANK YOU

Contact Us Today

Molnupiravir
EIDD-2801/MK-4482